$266 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 67 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 121.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IRIX | Buy | IRIDEX CORP | $17,687,000 | +18.2% | 1,220,611 | +20.6% | 6.64% | -7.7% |
| EVDY | Buy | EVERYDAY HEALTH INC | $11,920,000 | +60.1% | 1,550,000 | +64.0% | 4.48% | +25.1% |
| AERI | New | AERIE PHARMACEUTICALS INC | $10,567,000 | – | 280,000 | +100.0% | 3.97% | – |
| XBI | New | SPDR SERIES TRUSTput | $9,944,000 | – | 150,000 | +100.0% | 3.73% | – |
| EDGE | Buy | EDGE THERAPEUTICS INC | $7,318,000 | +36.6% | 703,000 | +32.6% | 2.75% | +6.7% |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $6,998,000 | +150.6% | 220,000 | +155.8% | 2.63% | +95.8% |
| MRVL | Buy | MARVELL TECHNOLOGY GROUP LTDord | $6,768,000 | +196.5% | 510,000 | +112.9% | 2.54% | +131.6% |
| CASM | Buy | CAS MED SYS INC | $6,647,000 | +3.2% | 3,845,365 | +9.8% | 2.50% | -19.4% |
| AKBA | Buy | AKEBIA THERAPEUTICS INC | $6,335,000 | +41.2% | 700,000 | +16.7% | 2.38% | +10.3% |
| Buy | IMMUNOMEDICS INCnote 4.750% 2/1 | $6,333,000 | +69.6% | 7,500,000 | +36.4% | 2.38% | +32.6% | |
| CEMI | Buy | CHEMBIO DIAGNOSTICS INC | $5,710,000 | +5610.0% | 771,676 | +6235.6% | 2.14% | +4366.7% |
| GWPH | New | GW PHARMACEUTICALS PLCads | $5,507,000 | – | 41,487 | +100.0% | 2.07% | – |
| WBMD | Buy | WEBMD HEALTH CORP | $4,722,000 | +225.0% | 95,000 | +280.0% | 1.77% | +154.0% |
| NBRV | Buy | NABRIVA THERAPEUTICS AGsponsored adr | $4,114,000 | -1.8% | 583,521 | +4.4% | 1.54% | -23.3% |
| VNDA | New | VANDA PHARMACEUTICALS INC | $4,093,000 | – | 245,995 | +100.0% | 1.54% | – |
| INNL | Buy | INNOCOLL HLDGS PLC | $3,902,000 | +24.7% | 671,517 | +18.2% | 1.46% | -2.6% |
| BCRX | New | BIOCRYST PHARMACEUTICALS | $2,445,000 | – | 554,448 | +100.0% | 0.92% | – |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $2,265,000 | +81.1% | 314,211 | +39.4% | 0.85% | +41.4% |
| AERI | New | AERIE PHARMACEUTICALS INCcall | $2,249,000 | – | 59,600 | +100.0% | 0.84% | – |
| RDUS | New | RADIUS HEALTH INC | $2,164,000 | – | 40,000 | +100.0% | 0.81% | – |
| GHDX | Buy | GENOMIC HEALTH INC | $2,085,000 | +65.0% | 72,100 | +47.7% | 0.78% | +29.0% |
| DBVT | New | DBV TECHNOLOGIES S Asponsored adr | $2,044,000 | – | 56,260 | +100.0% | 0.77% | – |
| ALR | New | ALERE INC | $1,946,000 | – | 45,000 | +100.0% | 0.73% | – |
| Buy | ESSA PHARMA INC | $1,678,000 | -4.3% | 586,700 | +2.9% | 0.63% | -25.3% | |
| AGIO | New | AGIOS PHARMACEUTICALS INC | $1,321,000 | – | 25,000 | +100.0% | 0.50% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INCcall | $1,272,000 | – | 40,000 | +100.0% | 0.48% | – |
| SVA | Buy | SINOVAC BIOTECH LTD | $1,206,000 | +53.4% | 204,358 | +54.2% | 0.45% | +19.8% |
| ONS | Buy | ONCOBIOLOGICS INC | $1,043,000 | +26.0% | 245,391 | +0.8% | 0.39% | -1.5% |
| AZN | New | ASTRAZENECA PLCsponsored adr | $986,000 | – | 30,000 | +100.0% | 0.37% | – |
| AGEN | New | AGENUS INC | $748,000 | – | 104,178 | +100.0% | 0.28% | – |
| THC | New | TENET HEALTHCARE CORP | $743,000 | – | 32,809 | +100.0% | 0.28% | – |
| EHIC | New | EHI CAR SVCS LTDspon ads cl a | $603,000 | – | 58,827 | +100.0% | 0.23% | – |
| CRBP | New | CORBUS PHARMACEUTICALS HLDGS | $552,000 | – | 81,302 | +100.0% | 0.21% | – |
| BCRX | New | BIOCRYST PHARMACEUTICALScall | $473,000 | – | 107,200 | +100.0% | 0.18% | – |
| RIGL | New | RIGEL PHARMACEUTICALS INCcall | $367,000 | – | 100,000 | +100.0% | 0.14% | – |
| TROV | Buy | TROVAGENE INCput | $359,000 | +52.1% | 80,000 | +53.8% | 0.14% | +19.5% |
| ARDX | New | ARDELYX INC | $337,000 | – | 26,076 | +100.0% | 0.13% | – |
| PGNX | New | PROGENICS PHARMACEUTICALS INcall | $253,000 | – | 40,000 | +100.0% | 0.10% | – |
| BCRX | New | BIOCRYST PHARMACEUTICALSput | $223,000 | – | 50,600 | +100.0% | 0.08% | – |
| AGTC | New | APPLIED GENETIC TECHNOL CORP | $100,000 | – | 10,193 | +100.0% | 0.04% | – |
| RIGL | New | RIGEL PHARMACEUTICALS INCput | $44,000 | – | 11,900 | +100.0% | 0.02% | – |
| PTX | Buy | PERNIX THERAPEUTICS HLDGS INput | $46,000 | +64.3% | 73,500 | +17.0% | 0.02% | +30.8% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.